You are here

Home » Reports

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 148 results
 
  • Record 1 TO 148

  1. Dendritic Cell Subset for Enhanced Cancer Vaccine

    SBC: Aastrom Biosciences, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Tumor antigen primed dendritic cells (DCs) are under widespread clinical evaluation for immunotherapy of multiple forms of cancer. Emerging evidence suggests that DCs are fundamental regulators of the immune response

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  2. Bioreactor for Enhanced T-cell Based Therapy of Melanoma

    SBC: Aastrom Biosciences, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Malignant melanoma is a significant and deadly form of cancer worldwide. Emerging evidence has shown that melanoma cells express tumor-associated antigens that are specifically recognized by the immune system. Melanom

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  3. Catheter to thermally classify atherosclerotic plaque

    SBC: ACCUMED SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this study will be to detect the prevalence and prognostic value of plaque temperature heterogeneity in diabetic patients undergoing stent implantation. The objective is to develop and commercialize a

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health

  4. Catheter to thermally classify atherosclerotic plaque

    SBC: ACCUMED SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this study will be to detect the prevalence and prognostic value of plaque temperature heterogeneity in diabetic patients undergoing stent implantation. The objective is to develop and commercialize an intraluminal Thermal Sensing System (TSS) for taking surface temperature measurements of atherosclerotic plaque lesions within the walls of cor ...

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  5. Akt Inhibitors to Treat Ewing's Sarcoma

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Novel drugs that improve overall survival with decreased morbidity are critical in the war on cancer. Acenta Discovery Inc. has partnered with the Toretsky Lab of the Lombardi Cancer Center to create and preclinically evaluate novel inhibitors of the protein Akt. An Akt inhibitor would have tremendous value in improving the lives of patients with many types ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  6. Caspase Inhibitor for Neuroprotection

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): An important role for apoptosis has been established in various pathological processes, particularly in nervous tissues. Apoptosis essentially contributes to neuronal loss during normal development, after acute neuronal injury, and in chronic degenerative conditions such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  7. Non-Invasive Drug Delivery to Treat Posterior Uveitis

    SBC: ACIONT, INC.            Topic: N/A

    Intermediate and posterior uveitis cause 10% of blindness in the U.S. The mainstay of therapy is to eradicate the infectious cause and to quell the inflammation with corticosteroids or immunosuppressants. Delivery of anti-inflammatory drugs to the posteri

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  8. SBIR TOPIC 192- BIOREACTOR TO MONITOR CNCR MMP'S

    SBC: ADVANCED SENSOR TECHNOLOGIES, INC.            Topic: N/A

    N/A

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  9. Load Bearing Bio-Active Bone Grafts

    SBC: SINTX TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A novel and promising approach for achieving bony repair especially for large bone defects is to transplant human bone marrow stromal cells or mesenchymal stem cells (hMSCs). Culture expanded hMSCs, transplanted into i

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  10. Novel Total Disc Implants

    SBC: SINTX TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Spinal disc herniation and the resulting symptoms of intractable pain, weakness, sensory loss, incontinence and progressive arthritis are among the most common debilitating conditions back problems. When conservative t

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government